secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2022-02-17T23:59:59+00:00
Accession:  0001104659-22-024496
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon FY21 rev $6.3B, adj. EPS $6.54; provides FY22 guide rev $6.1-$6.4B, adj. EBITDA margin 34-36%
--------------------------------------------------------------------------------

- FY21 revenue $6.3B (-3% as-reported vs 2020); GAAP diluted EPS $5.31; non-GAAP adj. diluted EPS $6.54.
- Q4 revenue $1.604B (-1% YoY); adj. EBITDA margin 34.2% vs 42.2% in prior year.
- Board declared $0.28 quarterly dividend payable March 17, 2022; record date Feb 28.
- FY22 guidance: revenue $6.1-$6.4B; adj. EBITDA margin 34%-36%; interest ~$400M; tax rate 17.5%-19.5%.
- Growth engines (Nexplanon, fertility, biosimilars) grew double digits; 4 business development deals since spin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465922024496/0001104659-22-024496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465922024496/tm227000d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-024496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer